Long-Term Prognostic Significance of Persisting Histological Activity Despite Biochemical Remission in Autoimmune Hepatitis

被引:96
作者
Dhaliwal, Harpreet K. [1 ]
Hoeroldt, Barbara S. [2 ]
Dube, Asha K. [3 ]
McFarlane, Elaine [1 ]
Underwood, James C. E. [4 ]
Karajeh, Mohammed A. [1 ]
Gleeson, Dermot [1 ]
机构
[1] Sheffield Teaching Hosp NHS Fdn Trust, Royal Hallamshire Hosp, Liver Unit, Sheffield, S Yorkshire, England
[2] Rotherham Gen Hosp, Dept Gastroenterol, Rotherham, S Yorkshire, England
[3] Sheffield Teaching Hosp NHS Fdn Trust, Dept Histopathol, Sheffield, S Yorkshire, England
[4] Univ Sheffield, Acad Unit Pathol, Sheffield, S Yorkshire, England
关键词
CORTICOSTEROID-THERAPY; AMINOTRANSFERASE LEVELS; LIVER-DISEASE; FIBROSIS; AZATHIOPRINE; MANAGEMENT; MAINTENANCE; CIRRHOSIS; RELAPSE; BIOPSY;
D O I
10.1038/ajg.2015.139
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVES: Biochemical remission is widely considered a satisfactory treatment end point in autoimmune hepatitis (AIH). The signifi cance of persisting histological activity despite biochemical remission is unknown. We aimed to assess the frequency and prognostic significance of persisting histological infl ammation in patients with AIH who had achieved biochemical remission with treatment. METHODS: We studied 120 patients (median age at diagnosis 57 years; 81% female) with AIH by International Criteria (59% definite), who received immunosuppressive treatment and underwent a follow-up liver biopsy after at least 6 months of sustained biochemical remission (defined as normal serum ALT and globulin). RESULTS: Fifty-five patients (46%) had persisting histological activity (Ishak histological activity index (HAI) >= 4). These patients had higher serum ALT (24 vs. 18 IU/l, P = 0.003) and AST (27 vs. 23 IU/l, P = 0.03) at the time of follow-up biopsy, compared with patients who achieved histological remission (HAI <= 3). They had less frequent regression of fibrosis on follow-up biopsy compared with those achieving histological remission (32 vs. 60%, P = 0.004) and had excess mortality (standardized mortality ratio 1.4 vs. 0.7, P < 0.05). The excess mortality was due to liver disease. On multivariate analysis, persisting histological activity was independently associated with all-cause death/transplantation (HR 3.1 (95% CI 1.2-8.1); P = 0.02); an association with liver-related death/transplantation fell short of signifi cance (HR 9.7 (95% CI 0.84-111.6; P = 0.07). CONCLUSIONS: Persisting histological activity, despite biochemical remission, is frequent in patients with treated AIH and is associated with lower rates of fibrosis regression and reduced long-term survival.
引用
收藏
页码:993 / 999
页数:7
相关论文
共 27 条
[1]   Effects of Serum Aspartate Aminotransferase Levels in Patients With Autoimmune Hepatitis Influence Disease Course and Outcome [J].
Al-Chalabi, Thawab ;
Underhill, James A. ;
Portmann, Bernard C. ;
McFarlane, Ian G. ;
Heneghan, Michael A. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2008, 6 (12) :1389-1395
[2]   International Autoimmune Hepatitis Group Report:: review of criteria for diagnosis of autoimmune hepatitis [J].
Alvarez, E ;
Berg, PA ;
Bianchi, FB ;
Bianchi, L ;
Burroughs, AK ;
Cancado, EL ;
Chapman, RW ;
Cooksley, WGE ;
Czaja, AJ ;
Desmet, VJ ;
Donaldson, RT ;
Eddleston, ALWF ;
Fainboim, L ;
Heathcote, J ;
Homberg, JC ;
Hoofnagle, JH ;
Kakumu, S ;
Krawitt, EL ;
Mackay, IR ;
MacSween, RNM ;
Maddrey, WC ;
Manns, MP ;
McFarlane, IG ;
zum Büschenfelde, KHM ;
Mieli-Vergani, G ;
Nakanuma, Y ;
Nishioka, M ;
Penner, E ;
Porta, G ;
Portmann, BC ;
Reed, WD ;
Rodes, J ;
Schalm, SW ;
Scheuer, PJ ;
Schrumpf, E ;
Seki, T ;
Toda, G ;
Tsuji, T ;
Tygstrup, N ;
Vergani, D ;
Zeniya, M .
JOURNAL OF HEPATOLOGY, 1999, 31 (05) :929-938
[4]   CONTROLLED PROSPECTIVE TRIAL OF CORTICOSTEROID THERAPY IN ACTIVE CHRONIC HEPATITIS [J].
COOK, GC ;
MULLIGAN, R ;
SHERLOCK, S .
QUARTERLY JOURNAL OF MEDICINE, 1971, 40 (158) :159-+
[5]   Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis [J].
Czaja, AJ ;
Carpenter, HA .
HEPATOLOGY, 2004, 39 (06) :1631-1638
[6]   Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis [J].
Czaja, AJ ;
Carpenter, HA .
JOURNAL OF HEPATOLOGY, 2004, 40 (04) :646-652
[7]  
CZAJA AJ, 1981, GASTROENTEROLOGY, V80, P687
[8]   British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis [J].
Gleeson, Dermot ;
Heneghan, Michael A. .
GUT, 2011, 60 (12) :1611-1629
[9]   Long-term Outcomes of Patients With Autoimmune Hepatitis Managed at a Nontransplant Center [J].
Hoeroldt, Barbara ;
McFarlane, Elaine ;
Dube, Asha ;
Basumani, Pandurangan ;
Karajeh, Mohammed ;
Campbell, Michael J. ;
Gleeson, Dermot .
GASTROENTEROLOGY, 2011, 140 (07) :1980-1989
[10]   HISTOLOGICAL GRADING AND STAGING OF CHRONIC HEPATITIS [J].
ISHAK, K ;
BAPTISTA, A ;
BIANCHI, L ;
CALLEA, F ;
DEGROOTE, J ;
GUDAT, F ;
DENK, H ;
DESMET, V ;
KORB, G ;
MACSWEEN, RNM ;
PHILLIPS, MJ ;
PORTMANN, BG ;
POULSEN, H ;
SCHEUER, PJ ;
SCHMID, M ;
THALER, H .
JOURNAL OF HEPATOLOGY, 1995, 22 (06) :696-699